Inhaled Heparin for Hospitalised COVID-19 Patients (INHALE-HEP)

  • End date
    Dec 1, 2022
  • participants needed
  • sponsor
    Australian National University
Updated on 25 March 2022


This meta-trial is a prospective collaborative individual participant data meta-analysis of randomised controlled trials and early phase studies. Individual studies will be conducted in multiple countries, including Australia, the UK, the USA, Ireland, Argentina, Brazil and Egypt.

Adult patients admitted to the hospital with confirmed SARS-CoV-2 infection, who do not require immediate mechanical ventilation, will be randomised to inhaled nebulised heparin or standard care for up to 21 days or until the patient has no respiratory symptoms. All studies will collect a minimum core dataset. The primary outcome for the meta-trial is the proportion of patients who receive invasive mechanical ventilation censored at day 28. Individual studies may have specific outcome measures in addition to the core set.

Condition Covid19
Treatment Unfractionated heparin
Clinical Study IdentifierNCT04635241
SponsorAustralian National University
Last Modified on25 March 2022


Yes No Not Sure

Inclusion Criteria

Patients admitted to hospital with COVID-19
No immediate requirement for mechanical ventilation (points 3-5 on the WHO ordinal scale)
Age equal to or greater than 18
Able to provide informed consent

Exclusion Criteria

Pregnant women
Known allergy to Heparin
Participant in another clinical trial that is not approved for joint enrollment
APTT> 120 seconds, not due to anticoagulant therapy
Platelet count <20 x 109 per L
Lung bleeding
Uncontrolled bleeding
Advanced neurological impairment
Advanced oncological disease
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note